Chemical Terrorism Attacks: Update on Antidotes

Emergency Medicine Clinics of North America

Volumn 25, Issue 2, 2007, Pages 567-595

  Lawrence, David T ^a   Kirk, Mark A ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; ACTIVATED CARBON; AMYL NITRITE; ANTIDOTE; ATROPINE; BENZODIAZEPINE DERIVATIVE; BOTULINUM ANTISERUM; CESIUM 137; CHOLINERGIC RECEPTOR BLOCKING AGENT; CYANIDE; DIAZEPAM; DIPHENHYDRAMINE; FERRIC FERROCYANIDE; FOSPHENYTOIN SODIUM; GLYCOPYRRONIUM BROMIDE; HYDROXOCOBALAMIN; LORAZEPAM; MANNITOL; MIDAZOLAM; ORGANOPHOSPHORUS COMPOUND; PENTOBARBITAL; POTASSIUM IODIDE; PRALIDOXIME; RADIOACTIVE MATERIAL; SARIN; SCOPOLAMINE; SODIUM NITRITE; SODIUM THIOSULFATE; THALLIUM; UNINDEXED DRUG;

ABSENCE OF SIDE EFFECTS; ALLERGIC REACTION; BLOOD PRESSURE; BOTULISM; CHEMICAL WARFARE; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTINUOUS INFUSION; CYANIDE POISONING; DRUG HYPERSENSITIVITY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; EMERGENCY CARE; HUMAN; HYPOTENSION; INTOXICATION; LOADING DRUG DOSE; MONOTHERAPY; NONHUMAN; PERNICIOUS ANEMIA; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RESPIRATION DEPRESSION; REVIEW; SEIZURE; SELF INJECTION; SIDE EFFECT; TACHYCARDIA; TERRORISM; THYROID CANCER; VASODILATATION;

EID: 34247578697     PISSN: 07338627     EISSN: 07338627     Source Type: Journal    
DOI: 10.1016/j.emc.2007.02.002     Document Type: Review

References (144)

1. Balali-Mood M., and Shariat M. Treatment of organophosphate poisoning. Experience of nerve agents and acute pesticide poisoning on the effects of oximes. J Physiol Paris 92 5-6 (1998) 375-378
2. Yanagisawa N, Morita H, Nakajima T. Sarin experiences in Japan: acute toxicity and long-term effects. J Neurol Sci 2006;249(1):76-85.
3. Cannard K. The acute treatment of nerve agent exposure. J Neurol Sci 2006;249(1):86-94.
4. Bajgar J. Complex view on poisoning with nerve agents and organophosphates. Acta Medica (Hradec Kralove) 48 1 (2005) 3-21
5. Lee E.C. Clinical manifestations of sarin nerve gas exposure. JAMA 290 5 (2003) 659-662
6. Leikin J.B., Thomas R.G., Walter F.G., et al. A review of nerve agent exposure for the critical care physician. [see comment]. Crit Care Med 30 10 (2002) 2346-2354
7. Newmark J. Therapy for nerve agent poisoning. Arch Neurol 61 5 (2004) 649-652
8. Bird S.B., Gaspari R.J., and Dickson E.W. Early death due to severe organophosphate poisoning is a centrally mediated process. Acad Emerg Med 10 4 (2003) 295-298
9. McDonough Jr. J.H., and Shih T.M. Neuropharmacological mechanisms of nerve agent-induced seizure and neuropathology. Neurosci Biobehav Rev 21 5 (1997) 559-579
10. Myhrer T., Skymoen L.R., and Aas P. Pharmacological agents, hippocampal eeg, and anticonvulsant effects on soman-induced seizures in rats. Neurotoxicology 24 3 (2003) 357-367
11. Sanada M, Zheng F, Huth T, et al. Cholinergic modulation of periaqueductal grey neurons: does it contribute to epileptogenesis after organophosphorus nerve agent intoxication? Toxicology, in press.
12. Sidell F. Nerve agents. In: Sidell F, Takafuji ET, Franz DR, editor. Medical aspects of chemical and biological warfare. Washington: Office of the Surgeon General at TMM publications; 1997. p. 129-80.
13. Newmark J. Nerve agents. Neurol Clin 23 2 (2005) 623-641
14. McDonough Jr. J.H., Zoefel L.D., McMonagle J., et al. Anticonvulsant treatment of nerve agent seizures: anticholinergics versus diazepam in soman-intoxicated guinea pigs. Epilepsy Res 38 1 (1999) 1-14
15. Shih T.M., and McDonough Jr. J.H. Organophosphorus nerve agents-induced seizures and efficacy of atropine sulfate as anticonvulsant treatment. Pharmacol Biochem Behav 64 1 (1999) 147-153
16. Keyes D. Chemical nerve agents. Medical response to terrorism: preparedness and clinical practice. In: Keyes D, editor. 1st edition. Philadelphia: Lippincott Williams and Wilkins; 2005. p. 2-15.
17. Weinbroum A.A. Pathophysiological and clinical aspects of combat anticholinesterase poisoning. Br Med Bull 72 1 (2005) 119-133
18. Newmark J. Nerve agents: pathophysiology and treatment of poisoning. Semin Neurol 24 2 (2004) 185-196
19. Newmark J. The birth of nerve agent warfare: lessons from Syed Abbas Foroutan. Neurology 62 9 (2004) 1590-1596
20. Holstege C.P., Kirk M., and Sidell F.R. Chemical warfare. Nerve agent poisoning. Crit Care Clin 13 4 (1997) 923-942
21. Cosar A., and Kenar L. An anesthesiological approach to nerve agent victims. Mil Med 171 1 (2006) 7-11
22. Gilat E., Kadar T., Levy A., et al. Anticonvulsant treatment of sarin-induced seizures with nasal midazolam: an electrographic, behavioral, and histological study in freely moving rats. Toxicol Appl Pharmacol 209 1 (2005) 74-85
23. McDonough Jr. J.H., McMonagle J., Copeland T., et al. Comparative evaluation of benzodiazepines for control of soman-induced seizures. Arch Toxicol 73 8-9 (1999) 473-478
24. Hayward I.J., Wall H.G., Jaax N.K., et al. Decreased brain pathology in organophosphate-exposed rhesus monkeys following benzodiazepine therapy. J Neurol Sci 98 1 (1990) 99-106
25. Shih T.M., Duniho S.M., and McDonough J.H. Control of nerve agent-induced seizures is critical for neuroprotection and survival. Toxicol Appl Pharmacol 188 2 (2003) 69-80
26. Marrs T.C. The role of diazepam in the treatment of nerve agent poisoning in a civilian population. Toxicol Rev 23 3 (2004) 145-157
27. Lallement G., Dorandeu F., Filliat P., et al. Medical management of organophosphate-induced seizures. J Physiol Paris 92 5-6 (1998) 369-373
28. Myhrer T., Anderson J.M., Nguyen N.H., et al. Soman-induced convulsions in rats terminated with pharmacological agents after 45 min: neuropathology and cognitive performance. Neurotoxicology 26 1 (2005) 39-48
29. McDonough J., Benjamin A., McMonagle J., et al. Effects of fosphenytoin on nerve agent-induced status epilepticus. Drug Chem Toxicol 27 1 (2004) 27-39
30. Eyer P. The role of oximes in the management of organophosphorus pesticide poisoning. Toxicol Rev 22 3 (2003) 165-190
31. Dickson E.W., Bird S.B., Gaspari R.J., et al. Diazepam inhibits organophosphate-induced central respiratory depression. Acad Emerg Med 10 12 (2003) 1303-1306
32. Kassa J. Review of oximes in the antidotal treatment of poisoning by organophosphorus nerve agents. J Toxicol Clin Toxicol 40 6 (2002) 803-816
33. Rotenberg J.S., and Newmark J. Nerve agent attacks on children: diagnosis and management. Pediatrics 112 3 (2003) 648-658
34. Johnson M.K., Vale J.A., Marrs T.C., et al. Pralidoxime for organophosphorus poisoning. [comment]. Lancet 340 8810 (1992) 64
35. Farrar H.C., Wells T.G., and Kearns G.L. Use of continuous infusion of pralidoxime for treatment of organophosphate poisoning in children. J Pediatr 116 4 (1990) 658-661
36. Tush G.M., and Anstead M.I. Pralidoxime continuous infusion in the treatment of organophosphate poisoning. Ann Pharmacother 31 4 (1997) 441-444
37. Bawaskar H.S., and Joshi S.R. Organophosphorus poisoning in agricultural India-status in 2005. [comment]. J Assoc Physicians India 53 (2005) 422-424
38. Medicis J.J., Stork C.M., Howland M.A., et al. Pharmacokinetics following a loading plus a continuous infusion of pralidoxime compared with the traditional short infusion regimen in human volunteers. J Toxicol Clin Toxicol 34 3 (1996) 289-295
39. Kamha A.A., Al Omary I.Y., Zalabany H.A., et al. Organophosphate poisoning in pregnancy: a case report. Basic Clin Pharmacol Toxicol 96 5 (2005) 397-398
40. Shivakumar S., Raghaven K., Ishaq R.M., et al. Organophosphorus poisoning: a study on the effectiveness of therapy with oximes. J Assoc Physicians India 54 (2006) 250-251
41. Tokuda Y., Kikuchi M., Takahashi O., et al. Prehospital management of sarin nerve gas terrorism in urban settings: 10 years of progress after the Tokyo subway sarin attack. Resuscitation 68 2 (2006) 193-202
42. Rahimi R., Nikfar S., and Abdollahi M. Increased morbidity and mortality in acute human organophosphate-poisoned patients treated by oximes: a meta-analysis of clinical trials. Hum Exp Toxicol 25 3 (2006) 157-162
43. Peter J.V., Moran J.L., and Graham P. Oxime therapy and outcomes in human organophosphate poisoning: an evaluation using meta-analytic techniques. Crit Care Med 34 2 (2006) 502-510
44. Eddleston M., Szinicz L., Eyer P., et al. Oximes in acute organophosphorus pesticide poisoning: a systematic review of clinical trials. QJM 95 5 (2002) 275-283
45. Aaron C. Safety of adult nerve agent autoinjectors in children. J Pediatr 146 1 (2005) 8-10
46. Foltin G., Tunik M., Curran J., et al. Pediatric nerve agent poisoning: medical and operational considerations for emergency medical services in a large American city. Pediatr Emerg Care 22 4 (2006) 239-244
47. Amitai Y., Almog S., Singer R., et al. Atropine poisoning in children during the Persian Gulf crisis. A national survey in Israel. JAMA 268 5 (1992) 630-632
48. Kozer E., Mordel A., Haim S.B., et al. Pediatric poisoning from trimedoxime (TMB4) and atropine automatic injectors. J Pediatr 146 1 (2005) 41-44
49. Krejcova G., and Kassa J. Anticholinergic drugs-functional antidotes for the treatment of tabun intoxication. Acta Medica (Hradec Kralove) 47 1 (2004) 13-18
50. Kventsel I., Berkovitch M., Reiss A., et al. Scopolamine treatment for severe extra-pyramidal signs following organophosphate (Chlorpyrifos) ingestion. Clinical Toxicology 43 7 (2005) 877-879
51. Bird S.B., Gaspari R.J., Lee W.J., et al. Diphenhydramine as a protective agent in a rat model of acute, lethal organophosphate poisoning. Acad Emerg Med 9 12 (2002) 1369-1372
52. Bania T.C., Chu J., Bailes D., et al. Jimson weed extract as a protective agent in severe organophosphate toxicity. Acad Emerg Med 11 4 (2004) 335-338
53. Gracia R. Cyanide. In: Keyes D, editor. Medical response to terrorism: preparedness and clinical practice. 1st edition. Philadelphia: Lippincott Williams and Wilkins; 2005. p. 26-37.
54. Holstege C., Isom G.E., and Kirk M.A. Cyanide and hydrogen sulfide. In: Flomenbaum N., Goldfrank L.R., Hoffman R.S., et al. (Eds). Goldfrank toxicological emergencies. 8th edition (2006), The McGraw-Hill Companies, Inc, New York 1712-1724
55. Eckstein M., and Maniscalco P.M. Focus on smoke inhalation-the most common cause of acute cyanide poisoning. Prehospital Disaster Med 21 2 Suppl. 2 (2006) s49-s55
56. Morocco A.P. Cyanides. Crit Care Clin 21 4 (2005) 691-705
57. DesLauriers C.A., Burda A.M., and Wahl M. Hydroxocobalamin as a cyanide antidote. Am J Ther 13 2 (2006) 161-165
58. Rotenberg J.S. Cyanide as a weapon of terror. Pediatr Ann 32 4 (2003) 236-240
59. Megarbane B., Delahaye A., Goldgran-Toladano D., et al. Antidotal treatment of cyanide poisoning. J Chin Med Assoc 66 4 (2003) 193-203
60. Dunea G. Death over the counter. Br Med J (Clin Res Ed) 286 6360 (1983) 211-212
61. Peddy S.B., Rigby M.R., and Shaffner D.H. Acute cyanide poisoning. Pediatr Crit Care Med 7 1 (2006) 79-82
62. Prieto I., Pujol I., Santiuste C., et al. Acute cyanide poisoning by subcutaneous injection. Emerg Med J 22 5 (2005) 389-390
63. Baud F.J., Borron S.W., Megarbane B., et al. Value of lactic acidosis in the assessment of the severity of acute cyanide poisoning. Crit Care Med 30 9 (2002) 2044-2050
64. Rebeca G., and Greene S. Cyanide poisoning and its treatment. Pharmacotherapy 24 10 (2004) 1358-1365
65. LaPostolle F., Borron S., and Baud F. Increased plasma lactate concentrations are associated with cyanide but not other types of acute poisoning. Clinical Toxicology 44 5 (2006) 777
66. Martin-Bermudez R., Maestre-Romero A., Goni-Belzunegui M.V., et al. Venous blood arteriolization and multiple organ failure after cyanide poisoning. Intensive Care Med 23 12 (1997) 1286
67. Geller R.J., Barthold C., Saiers J., et al. Pediatric cyanide poisoning: causes, manifestations, management, and unmet needs. Pediatrics 118 5 (2006) 2146-2158
68. Howland A. Sodium and amyl nitrites. In: Flomenbaum N., Goldfrank L.R., Hoffman R.S., et al. (Eds). Goldfrank's toxicological emergencies. 8th edition (2006), The McGraw-Hill Company, New York 1725-1730
69. Breen P.H., Isserles S.A., Westley J., et al. Effect of oxygen and sodium thiosulfate during combined carbon monoxide and cyanide poisoning. Toxicol Appl Pharmacol 134 2 (1995) 229-234
70. Guidotti T. Acute cyanide poisoning in prehospital care: new challenges, new tools for intervention. Prehospital Disaster Med 21 2 Suppl. 2 (2006) s40-s48
71. Sauer S.W., and Keim M.E. Hydroxocobalamin: improved public health readiness for cyanide disasters. Ann Emerg Med 37 6 (2001) 635-641
72. Kirk M.A., Gerace R., and Kulig K.W. Cyanide and methemoglobin kinetics in smoke inhalation victims treated with the cyanide antidote kit. Ann Emerg Med 22 9 (1993) 1413-1418
73. Baskin S.I., Horowitz A.M., and Nealley E.W. The antidotal action of sodium nitrite and sodium thiosulfate against cyanide poisoning. J Clin Pharmacol 32 4 (1992) 368-375
74. Dart R. Hydroxocobalamin for acute cyanide poisoning: new data from preclinical and clinical studies; new results from the prehospital emergency setting. Clinical Toxicology 44 Suppl 1 (2006) 1-3
75. Posner M.A., Tobey R.E., and McElroy H. Hydroxocobalamin therapy of cyanide intoxication in guinea pigs. Anesthesiology 44 2 (1976) 157-160
76. Posner M.A., Rodkey F.L., and Tobey R.E. Nitroprusside-induced cyanide poisoning: antidotal effect of hydroxocobalamin. Anesthesiology 44 4 (1976) 330-335
77. Rose C.L., Worth R.M., and Chen K.K. Hydroxo-cobalamine and acute cyanide poisoning in dogs. Life Sci 4 18 (1965) 1785-1789
78. Borron S.W. Recognition and treatment of acute cyanide poisoning. J Emerg Nurs 32 4 Suppl. 1 (2006) S12-S18
79. Mannaioni G., Vannacci A., Marzocca C., et al. Acute cyanide intoxication treated with a combination of hydroxycobalamin, sodium nitrite, and sodium thiosulfate. J Toxicol Clin Toxicol 40 2 (2002) 181-183
80. Fortin J.L., Giocanti J.P., Ruttiman M., et al. Prehospital administration of hydroxocobalamin for smoke inhalation-associated cyanide poisoning: 8 years of experience in the paris fire brigade. Clinical Toxicology 44 Suppl 1 (2006) 37-44
81. Forsyth JC, Mueller PD, Becker CE, et al. Hydroxocobalamin as a cyanide antidote: safety, efficacy and pharmacokinetics in heavily smoking normal volunteers. J Toxicol Clin Toxicol 1993;31(2):277-94.
82. Gerth K., Ehring T., Braendle M., et al. Nitric oxide scavenging by hydroxocobalamin may account for its hemodynamic profile. Clinical Toxicology 44 Suppl 1 (2006) 29-36
83. Borron S., Stonerook M., and Reid F. Efficacy of hydroxocobalamin for the treatment of acute cyanide poisoning in adult beagle dogs. Clinical Toxicology 44 Suppl 1 (2006) 5-15
84. Riou B., Bereaux A., Pussard E., et al. Comparison of the hemodynamic effects of hydroxocobalamin and cobalt edetate at equipotent cyanide antidotal doses in conscious dogs. Intensive Care Med 19 1 (1993) 26-32
85. Howland A. Hydroxocobalamin. In: Flomenbaum N., Goldfrank L.R., Hoffman R.S., et al. (Eds). Goldfrank's toxicological emergencies. 8th edition (2006), The McGraw-Hill company, New York 1731-1733
86. Hall AHBH Rumack. Hydroxycobalamin/sodium thiosulfate as a cyanide antidote. J Emerg Med 5 2 (1987) 115-121
87. Froyshov S., Hoiseth G., and Jacobsen D. Cyanide intoxication: course before and after treatment with antidote. Clinical Toxicology 44 5 (2006) 763
88. Curry S.C., Connor D.A., and Raschke R.A. Effect of the cyanide antidote hydroxocobalamin on commonly ordered serum chemistry studies. Ann Emerg Med 24 1 (1994) 65-67
89. Uhl W., Nolting A., Golor G., et al. Safety of hydroxocobalamin in healthy volunteers in a randomized, placebo-controlled study. Clinical Toxicology 44 Suppl 1 (2006) 17-28
90. Bromley J., Hughes B.G.M., Leong D.C.S., et al. Life-threatening interaction between complementary medicines: cyanide toxicity following ingestion of amygdalin and vitamin C. Ann Pharmacother 39 9 (2005) 1566-1569
91. Weng T.I., Fang C.C., Lin S.M., et al. Elevated plasma cyanide level after hydroxocobalamin infusion for cyanide poisoning. Am J Emerg Med 22 6 (2004) 492-493
92. Dart R.C., Stark Y., Fulton B., et al. Insufficient stocking of poisoning antidotes in hospital pharmacies. JAMA 276 18 (1996) 1508-1510
93. Dart R.C., Goldfrank L.R., Chyka P.A., et al. Combined evidence-based literature analysis and consensus guidelines for stocking of emergency antidotes in the United States. Ann Emerg Med 36 2 (2000) 126-132
94. Brivet F., Delfraissy J.F., Duche M., et al. Acute cyanide poisoning: recovery with non-specific supportive therapy. Intensive Care Med 9 1 (1983) 33-35
95. Graham D.L., Laman D., Theodore J., et al. Acute cyanide poisoning complicated by lactic acidosis and pulmonary edema. Arch Intern Med 137 8 (1977) 1051-1055
96. Horowitz B.Z. Botulinum toxin. Crit Care Clin 21 4 (2005) 825-839
97. Gupta A., Sumner C.J., Castor M., et al. Adult botulism type F in the United States, 1981-2002. Neurology 65 11 (2005) 1694-1700
98. Keet C.A., Fox C.K., Margeta M., et al. Infant botulism, type F, presenting at 54 hours of life. Pediatr Neurol 32 3 (2005) 193-196
99. Timmons R, Carbone A. Botulism: the most toxic substance known. In: Keyes DC, editor. Medical response to terrorism: preparedness and clinical practice. 1st edition. New York: Lippincott Williams and Wilkins; 2005. p. 117-26.
100. Patocka J., Splino M., and Merka V. Botulism and bioterrorism: how serious is this problem?. Acta Medica (Hradec Kralove) 48 1 (2005) 23-28
101. Souayah N., Karim H., Kamin S.S., et al. Severe botulism after focal injection of botulinum toxin. Neurology 67 (2006) 1855-1856
102. Grumelli C., Verderio C., Pozzi D., et al. Internalization and mechanism of action of clostridial toxins in neurons. Neurotoxicology 26 5 (2005) 761-767
103. Cherington M. Botulism: update and review. Semin Neurol 24 2 (2004) 155-163
104. Arnon S.S., Schechter R., Inglesby T.V., et al. Botulinum toxin as a biological weapon: medical and public health management. [erratum appears in JAMA 2001 Apr 25;285(16):2081]. JAMA 285 8 (2001) 1059-1070
105. Robinson R.F., and Nahata M.C. Management of botulism. Ann Pharmacother 37 1 (2003) 127-131
106. Villar R.G., Elliott S.P., and Davenport K.M. Botulism: the many faces of botulinum toxin and its potential for bioterrorism. Infect Dis Clin North Am 20 2 (2006) 313-327
107. Sobel J. Botulism. Clin Infect Dis 41 8 (2005) 1167-1173
108. Penas S.C., Faria O.M., Serrao R., et al. Ophthalmic manifestations in 18 patients with botulism diagnosed in Porto, Portugal between 1998 and 2003. J Neuroophthalmol 25 4 (2005) 262-267
109. Varma J.K., Katsitadze G., Moiscrafishvili T., et al. Signs and symptoms predictive of death in patients with foodborne botulism-Republic of Georgia, 1980-2002. [see comment]. Clin Infect Dis 39 3 (2004) 357-362
110. Anonymous. Botulism: treatment overview for clinicians. 6/14/2006. Available at: www.bt.cdc.gov/agent/Botulism/clinicians/treatment.asp. Accessed October 9, 2006.
111. Black R.E., and Gunn R.A. Hypersensitivity reactions associated with botulinal antitoxin. Am J Med 69 4 (1980) 567-570
112. Arnon S.S., Schechter R., Maslanka S.E., et al. Human botulism immune globulin for the treatment of infant botulism. [see comment]. N Engl J Med 354 5 (2006) 462-471
113. Fox C.K., Keet C.A., and Strober J.B. Recent advances in infant botulism. Pediatr Neurol 32 3 (2005) 149-154
114. Rusyniak D.E., Furbee R.B., and Kirk M.A. Thallium and arsenic poisoning in a small midwestern town. Ann Emerg Med 39 3 (2002) 307-311
115. Pau P.W. Management of thallium poisoning. Hong Kong Med J 6 3 (2000) 316-318
116. Vergauwe P.L., Knockaert D.C., and Van Tittelboom T.J. Near fatal subacute thallium poisoning necessitating prolonged mechanical ventilation. Am J Emerg Med 8 6 (1990) 548-550
117. Questel F., Dugarin J., and Dally S. Thallium-contaminated heroin. Ann Intern Med 124 6 (1996) 616
118. Insley B.M., Grufferman S., and Ayliffe H.E. Thallium poisoning in cocaine abusers. Am J Emerg Med 4 6 (1986) 545-548
119. Wainwright A.P., Kox W.J., House I.M., et al. Clinical features and therapy of acute thallium poisoning. Q J Med 69 259 (1988) 939-944
120. Malbrain MLNG, Lambrecht GLY, Zandijk E, et al. Treatment of severe thallium intoxication. Journal of Toxicology: Clinical Toxicolgy 1997;35(1):97-100.
121. Rusyniak DE, Kao LW, Nanagas KA, et al. Dimercaptosuccinic acid and prussian blue in the treatment of acute thallium poisoning in rats. Journal of Toxicology: Clinical Toxicology 2003;41(2):137-42.
122. Hoffman R.S. Thallium toxicity and the role of prussian blue in therapy. Toxicol Rev 22 1 (2003) 29-40
123. Jha S., Kumar R., and Kumar R. Thallium poisoning presenting as paresthesias, paresis, psychosis and pain in abdomen. J Assoc Physicians India 54 (2006) 53-55
124. Tsai Y.T., Huang C.C., Kuo H.C., et al. Central nervous system effects in acute thallium poisoning. Neurotoxicology 27 2 (2006) 291-295
125. Tabandeh H., Crowston J.G., and Thompson G.M. Ophthalmologic features of thallium poisoning. Am J Optho 117 n2 (1994) 243-245
126. Ibrahim D., Froberg B., Wolf A., et al. Heavy metal poisoning: clinical presentations and pathophysiology. Clin Lab Med 26 1 (2006) 67-97
127. Galvan-Arzate S., and Santamaria A. Thallium toxicity. Toxicol Lett 99 1 (1998) 1-13
128. Thompson, DF, Callen ED. Soluble or insoluble prussian blue for radiocesium and thallium poisoning Ann Pharmacother, 2004;38(9):1509-14.
129. Atsmon J., Taliansky E., Landau M., et al. Thallium poisoning in Israel. Am J Med Sci 320 5 (2000) 327-330
130. Kamerbeek H.H., Rauws A.G., ten Ham M., et al. Prussian blue in therapy of thallotoxicosis. An experimental and clinical investigation. Acta Med Scand 189 4 (1971) 321-324
131. Bhardwaj N., Bhatnager A., Pathak D.P., et al. Dynamic, equilibrium and human studies of adsorption of 201Tl by prussian blue. Health Phys 90 3 (2006) 250-257
132. Hoffman R.S. Prussian blue. In: Flomenbaum N., Goldfrank L.R., Hoffman R.S., et al. (Eds). Goldfrank's toxicological emergencies. 8th edition (2006), The McGraw-Hill Companies, Inc, New York 1373-1377
133. Stevens W., van Peteghem C., Heyndrickx A., et al. Eleven cases of thallium intoxication treated with prussian blue. Int J Clin Pharmacol Ther Toxicol 10 1 (1974) 1-22
134. Pearce J. Studies of any toxicological effects of prussian blue compounds in mammals-a review. Food Chem Toxicol 32 6 (1994) 577-582
135. Hoffman R., Hoffman R., Stringer J., et al. Comparative efficacy of thallium adsorption by activated charcoal, prussian blue, and sodium polystyrene sulfonate. J Toxicol Clin Toxicol 37 7 (1999) 833-837
136. Goans R.E., and Waselenko J.K. Medical management of radiological casualties. Health Phys 89 5 (2005) 505-512
137. Koenig K.L., Goans R.E., Hatchett R.J., et al. Medical treatment of radiological casualties: current concepts. Ann Emerg Med 45 6 (2005) 643-652
138. Waselenko J.K., MacVittie T.J., Blakely W.F., et al. Medical management of the acute radiation syndrome: recommendations of the Strategic National Stockpile Radiation Working Group. Ann Intern Med 140 12 (2004) 1037-1051
139. Cardis E., Kesminiene A., Ivanov V., et al. Risk of thyroid cancer after exposure to 131I in childhood. J Natl Cancer Inst 97 10 (2005) 724-732
140. Verger P., Aurengo A., Geoffroy B., et al. Iodine kinetics and effectiveness of stable iodine prophylaxis after intake of radioactive iodine: a review. Thyroid 11 4 (2001) 353-360
141. Schneider A.B., Becker D.V., and Robbins J. Protecting the thyroid from accidental or terrorist-instigated 131I releases. Thyroid 12 4 (2002) 271-272
142. Anonymous. Guidance: potassium iodide as a thyroid blocking agent in radiation emergencies. December 10, 2001. Available at: www.fda.gov/cder/guidance/index.index. Accessed September 21, 2006.
143. Vastag B. Experts advise on potassium iodide use: no protection against "dirty bombs. JAMA 289 16 (2003) 2058
144. Dennis F.T., and Chelsea O.C. Prussian blue for treatment of radiocesium poisoning. Pharmacotherapy 21 11 (2001) 1364-1367